SUBSCRIBE
SUBSCRIBE

Kardigan

NEWS
Yellow diagram of pulses on a stack of red paper hearts. Illustration of the concept of healthy lifestyles and cardiovascular related diseases
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
March 30, 2026
 · 
2 min read
 · 
Annalee Armstrong
NextGen
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
Vector design of a human heart with flat color and multiple colors line heart shapes. Square composition.
Series A
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
January 10, 2025
 · 
2 min read
 · 
Heather McKenzie
  • NextGen Class of 2026 Badge
JOBS
IN THE PRESS
Press Releases
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
March 30, 2026
 · 
7 min read
Press Releases
Kardigan Announces Multiple Presentations at ACC.26 from its Late-Stage Portfolio of Personalized Cardiovascular Medicines
March 17, 2026
 · 
6 min read
Press Releases
Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026
January 7, 2026
 · 
5 min read
Press Releases
Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025
November 10, 2025
 · 
5 min read
Press Releases
Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform
November 6, 2025
 · 
5 min read
Press Releases
Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio of Personalized Cardiovascular Medicines
October 15, 2025
 · 
2 min read
Press Releases
Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025
September 30, 2025
 · 
5 min read
Press Releases
Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis
September 25, 2025
 · 
6 min read
Press Releases
Kardigan Launches with Industry-Leading Team to Modernize Cardiovascular Drug Development with Late-Stage Portfolio of Personalized Medicines
January 10, 2025
 · 
4 min read